Overview
Introduction
Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage
breast cancer. In recent days, however, agents such as Sanofi-Aventiss Taxotere and AstraZenecas
Arimidex have been gaining prominence. This report examines the current treatment paradigms for
early-stage breast cancer, based on primary research data from 180 physicians in the seven major
markets.
Scope
- Analysis of current treatment practices for early-stage breast cancer based on primary research
from 180 physicians in the seven major markets
- Physician awareness and ratings of late-stage pipeline drugs for breast cancer, including
recently launched APPs Abraxane and GSKs lapatinib
Report Highlights
Sanofi-Aventiss Taxotere (docetaxel) is likely to see a significant increase in its use as
adjuvant and neoadjuvant therapies in combination with anthracycline-based regimens. However,
Sanofi-Aventis will need to disseminate relevant trial results to physicians to compete with the
likes of paclitaxel, especially in the US.
AstraZenecas Arimidex (anastrozole) will replace tamoxifen as the gold-standard adjuvant therapy
for local and locally advanced breast cancer, given the latest ATAC trial results in December 2004.
Abraxane (albumin-bound paclitaxel) had the highest awareness rate among late-stage pipeline
drugs, as well as being considered the most promising agent. Its recent launch and potential success
in metastatic disease is likely to be translated into the adjuvant and neoadjuvant settings.
Reasons to Purchase
- Identify the key chemotherapy regimens in the neoadjuvant and adjuvant settings for local and
locally-advanced breast cancer
- Target physicians effectively through an understanding of prescribing behavior for antihormonal
agents in pre- and postmenopausal breast cancer
- Evaluate product potential by assessing physician awareness and rating of key late-stage
pipeline drugs for breast cancer
| 
View Cart
